Table 3.

Association between gene polymorphisms in NER pathway and overall survival of gastric cancer

Gene	Total	%	Progression N=171	%	Adjusted HR (95% CI)	P value	Death N=97	%	Overall survival time (month)	Log-rank test	Adjusted HR (95% CI)	P value
ERCC1 rs11615
TT	162	39.5	73	42.7	1.0 (Ref.)		43	44.3	31.4		1.0 (Ref.)	-
TC	187	45.6	75	43.9	0.82 (0.52-1.28)	0.35	41	42.3	33.5		0.78 (0.46-1.31)	0.31
CC	61	14.9	23	13.5	0.74 (0.38-1.40)	0.32	13	13.4	34.1	0.27	0.75 (0.34-1.58)	0.42
ERCC1 rs3212986
GG	187	45.6	91	53.2	1.0 (Ref.)		55	56.7	27.8		1.0 (Ref.)	-
GT	169	41.2	66	38.6	0.68 (0.43-1.05)	0.07	35	36.1	34.7		0.63 (0.37-1.05)	0.06
TT	54	13.2	14	8.2	0.37 (0.17-0.75)	0.00	7	7.2	37.5	<0.05	0.36 (0.13-0.87)	0.01
ERCC2 rs13181
AA	158	38.5	77	45.0	1.0 (Ref.)		47	48.5	28.5		1.0 (Ref.)	-
AC	175	42.7	70	40.9	0.70 (0.44-1.11)	0.11	38	39.2	34.6		0.66 (0.39-1.11)	0.09
CC	77	18.8	24	14.0	0.48 (0.26-0.88)	0.01	12	12.4	37.2	<0.05	0.44 (0.20-0.91)	0.02
ERCC2 rs1799793
GG	174	42.4	78	45.6	1.0 (Ref.)		45	46.4	32.7		1.0 (Ref.)	-
GA	188	45.9	75	43.9	0.82 (0.53-1.27)	0.34	42	43.3	33.6		0.82 (0.49-1.38)	0.43
AA	48	11.7	18	10.5	0.74 (0.36-1.49)	0.36	10	10.3	34.2	0.14	0.75 (0.31-1.71)	0.47
ERCC5 rs17655
CC	183	44.6	79	46.2	1.0 (Ref.)		47	48.5	32.5		1.0 (Ref.)	-
CG	174	42.4	70	40.9	0.74 (0.36-1.49)	0.36	39	40.2	32.9		0.84 (0.50-1.40)	0.47
GG	73	17.8	22	12.9	0.89 (0.57-1.38)	0.57	11	11.3	35.2	0.28	0.51 (0.23-1.09)	0.07
XPA rs1800975
AA	194	47.3	86	50.3	1.0 (Ref.)		49	50.5	33.1		1.0 (Ref.)	-
AG	165	40.2	66	38.6	0.84 (0.54-1.30)	0.41	37	38.1	33.6		0.86 (0.51-1.43)	0.53
GG	51	12.4	19	11.1	0.75 (0.37-1.47)	0.36	11	11.3	34.5	0.25	0.81 (0.35-1.78)	0.59
XPC rs2228001
AA	215	52.4	94	55.0	1.0 (Ref.)		55	56.7	32.8		1.0 (Ref.)	-
AC	128	31.2	52	30.4	0.88 (0.55-1.41)	0.57	29	29.9	33.7		0.85 (0.49-1.47)	0.54
CC	67	16.3	25	14.6	0.77 (0.42-1.39)	0.35	13	13.4	34.5	0.19	0.70 (0.33-1.43)	0.3